Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 1
1990 1
1994 1
1997 2
1998 1
1999 2
2001 1
2002 3
2003 5
2004 5
2005 2
2006 2
2007 5
2008 4
2009 5
2010 4
2011 2
2012 5
2013 5
2014 6
2015 6
2016 6
2017 2
2018 7
2019 12
2020 3
2021 10
2022 13
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, Liu MC, Martin N, Papi A, Roufosse F, Steinfeld J, Wechsler ME, Yancey SW. Pavord ID, et al. Allergy. 2022 Mar;77(3):778-797. doi: 10.1111/all.15056. Epub 2021 Sep 16. Allergy. 2022. PMID: 34402066 Free PMC article. Review.
Mepolizumab is a humanized monoclonal antibody that binds to and neutralizes interleukin-5, the major cytokine involved in eosinophil proliferation, activation, and survival. ...Here, we review the development, approval, and real-world effectiveness of mepolizumab for the …
Mepolizumab is a humanized monoclonal antibody that binds to and neutralizes interleukin-5, the major cytokine involved in eosinophil …
FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes.
Yang W, He R, Qu H, Lian W, Xue Y, Wang T, Lin W, Zhu P, Xia M, Lai L, Wang Q. Yang W, et al. Cell Mol Immunol. 2023 Mar;20(3):292-304. doi: 10.1038/s41423-023-00973-7. Epub 2023 Jan 25. Cell Mol Immunol. 2023. PMID: 36693922 Free PMC article.
Psoriasis is a common chronic inflammatory skin disease characterized by inflammatory cell infiltration and epidermal hyperplasia. However, the regulatory complexity of cytokine and cellular networks still needs to be investigated. Here, we show that the expression of FXYD …
Psoriasis is a common chronic inflammatory skin disease characterized by inflammatory cell infiltration and epidermal hyperplasia. However, …
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team; Robinson DR, Chinnaiyan AM. Wu YM, et al. Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034. Cell. 2018. PMID: 29906450 Free PMC article.
Association Between Depression and Severity of Dry Eye Symptoms, Signs, and Inflammatory Markers in the DREAM Study.
Zhou Y, Murrough J, Yu Y, Roy N, Sayegh R, Asbell P, Maguire MG, Ying GS; DREAM Study Research Group. Zhou Y, et al. JAMA Ophthalmol. 2022 Apr 1;140(4):392-399. doi: 10.1001/jamaophthalmol.2022.0140. JAMA Ophthalmol. 2022. PMID: 35266971 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: Secondary cross-sectional and longitudinal analysis performed in April to December 2020 of data from Dry Eye Assessment and Management (DREAM) study, a randomized clinical trial from October 2014 to July 2016 including patients with moder …
DESIGN, SETTING, AND PARTICIPANTS: Secondary cross-sectional and longitudinal analysis performed in April to December 2020 of data from Dry …
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H. Khatri S, et al. J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. doi: 10.1016/j.jaci.2018.09.033. Epub 2018 Oct 23. J Allergy Clin Immunol. 2019. PMID: 30359681 Free article. Clinical Trial.
METHODS: COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT0100 …
METHODS: COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859) was an open-label extension …
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
Fakih M, Harb W, Mahadevan D, Babiker H, Berlin J, Lillie T, Krige D, Carter J, Cox C, Patel M, Parfitt L, Powell M, Rosen L. Fakih M, et al. J Immunother Cancer. 2023 Apr;11(4):e006561. doi: 10.1136/jitc-2022-006561. J Immunother Cancer. 2023. PMID: 37094988 Free PMC article. Clinical Trial.
Co-primary objectives were safety/tolerability and maximum tolerated dose and/or maximum feasible dose (MTD/MFD) of enadenotucirev plus nivolumab. Additional endpoints included response rate, cytokine responses, and anti-tumor immune responses. RESULTS: Overall, 51 heavily …
Co-primary objectives were safety/tolerability and maximum tolerated dose and/or maximum feasible dose (MTD/MFD) of enadenotucirev plus nivo …
Association of Tear Cytokine Concentrations with Symptoms and Signs of Dry Eye Disease: Baseline Data from the Dry Eye Assessment and Management (DREAM) Study.
Roy NS, Wei Y, Ying GS, Maguire MG, Asbell PA; Dry Eye Assessment and Management (DREAM) Study Group. Roy NS, et al. Curr Eye Res. 2023 Apr;48(4):339-347. doi: 10.1080/02713683.2022.2162088. Epub 2023 Jan 11. Curr Eye Res. 2023. PMID: 36632643 Free PMC article.
PURPOSE: To describe tear concentrations of IL-1beta, Il-6, IL-8, IL-10, IL-17A, IFNgamma and TNFalpha in tears, collected by microcapillaries, and their correlation with symptoms and signs in subjects with dry eye disease (DED) in the DREAM Study. METHODS: Cytokine …
PURPOSE: To describe tear concentrations of IL-1beta, Il-6, IL-8, IL-10, IL-17A, IFNgamma and TNFalpha in tears, collected by microcapillari …
Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study.
Roy NS, Yu Y, Ying GS, Maguire MG, Asbell PA; DREAM Study Group. Roy NS, et al. Eye Contact Lens. 2022 Sep 1;48(9):384-390. doi: 10.1097/ICL.0000000000000916. Epub 2022 Jun 30. Eye Contact Lens. 2022. PMID: 35916880 Free PMC article. Clinical Trial.
At baseline, 6 and 12 months, HLA-DR expression in conjunctival total, epithelial, and white blood cells and cytokine concentration in tears were determined. Differences in change from baseline between treatment groups were assessed using generalized estimating equations ( …
At baseline, 6 and 12 months, HLA-DR expression in conjunctival total, epithelial, and white blood cells and cytokine concentration i …
Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation.
Li J, Kumari T, Barazia A, Jha V, Jeong SY, Olson A, Kim M, Lee BK, Manickam V, Song Z, Clemens R, Razani B, Kim J, Dinauer MC, Cho J. Li J, et al. J Exp Med. 2022 Jan 3;219(1):e20211083. doi: 10.1084/jem.20211083. Epub 2021 Nov 9. J Exp Med. 2022. PMID: 34751735 Free PMC article.
Neutrophil DREAM promotes degranulation through IKKbeta-mediated SNAP-23 phosphorylation. Using sickle cell disease mice lacking DREAM, we show that hematopoietic DREAM promotes vaso-occlusive events in microvessels following TNF-alpha challenge. ...
Neutrophil DREAM promotes degranulation through IKKbeta-mediated SNAP-23 phosphorylation. Using sickle cell disease mice lacking D …
124 results